Filer Snapshot

ELITE PHARMACEUTICALS INC /NV/

CIK 0001053369. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

33

Latest filing

29 Jun 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: Forms 3/4/5 owner position for ELTP. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open owner activity Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC filing 10-K

10-K filed on 29 Jun 2026 for CIK 0001053369.

View source filing
Listed symbols
ELTP on OTC
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

Forms 3/4/5 positions$129K

Reporting-owner positions with enough filing detail to estimate value.

Forms 3/4/5 position value

3/4/5
$129K

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

ELTP
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
165 Ludlow Avenue, Northvale, NJ, 07647
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
NJ
Fiscal year end
31 March
Former names on EDGAR
ELITE PHARMACEUTICALS INC /DE/ (to 08 Feb 2012)

Filer intelligence

What SEC filings say about ELITE PHARMACEUTICALS INC /NV/

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • Forms 3/4/5 show insider context for ELTP worth $129K.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

Forms 3/4/5 insider context

ELTP

22 Aug 2025 · EVP Operations

$129K
Issuer page Owner page

Latest update

What changed recently for ELITE PHARMACEUTICALS INC /NV/

New fact period available

Latest financial period: Q1 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

29 Jun 2026

Page type

Company facts

Latest period

Q1 2026

SEC-backed company facts were refreshed from filings filed on 29 Jun 2026.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

ELITE PHARMACEUTICALS INC /NV/ has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q1 2026. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 29 Jun 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001053369 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
33
First seen
19 May 2021
Latest filing
29 Jun 2026
Entity
Company

Observed form types

10-K 10-Q 3 4 4/A

CIK-linked evidence first

ELITE PHARMACEUTICALS INC /NV/ SEC filings ELITE PHARMACEUTICALS INC /NV/ owner filings ELITE PHARMACEUTICALS INC /NV/ insider transactions ELITE PHARMACEUTICALS INC /NV/ company facts Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 33 SEC filings for ELITE PHARMACEUTICALS INC /NV/.

Open full filing history
10-K

10-K filing

Filing date
29 Jun 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
17 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
13 Jan 2026
Reporting date
09 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
14 Nov 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
03 Oct 2025
Reporting date
02 Oct 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
26 Aug 2025
Reporting date
22 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
14 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
25 Jul 2025
Reporting date
10 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
10 Jul 2025
Reporting date
08 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
08 Jul 2025
Reporting date
08 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-K

10-K filing

Filing date
30 Jun 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
13 Feb 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .